VERTEX PHARMACEUTICALS INC (VX1.DE) Fundamental Analysis & Valuation

FRA:VX1 • US92532F1003

Current stock price

370.65 EUR
-3.4 (-0.91%)
Last:

This VX1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. VX1.DE Profitability Analysis

1.1 Basic Checks

  • VX1 had positive earnings in the past year.
  • In the past year VX1 had a positive cash flow from operations.
  • VX1 had positive earnings in 4 of the past 5 years.
  • VX1 had a positive operating cash flow in 4 of the past 5 years.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • VX1 has a better Return On Assets (15.42%) than 89.29% of its industry peers.
  • VX1 has a Return On Equity of 21.18%. This is amongst the best in the industry. VX1 outperforms 88.10% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.14%, VX1 belongs to the best of the industry, outperforming 90.48% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for VX1 is above the industry average of 13.21%.
Industry RankSector Rank
ROA 15.42%
ROE 21.18%
ROIC 15.14%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • VX1 has a Profit Margin of 32.94%. This is amongst the best in the industry. VX1 outperforms 89.29% of its industry peers.
  • VX1's Profit Margin has declined in the last couple of years.
  • VX1's Operating Margin of 39.04% is amongst the best of the industry. VX1 outperforms 89.29% of its industry peers.
  • In the last couple of years the Operating Margin of VX1 has declined.
  • The Gross Margin of VX1 (86.24%) is better than 76.19% of its industry peers.
  • In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
Industry RankSector Rank
OM 39.04%
PM (TTM) 32.94%
GM 86.24%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. VX1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so VX1 is still creating some value.
  • VX1 has less shares outstanding than it did 1 year ago.
  • VX1 has less shares outstanding than it did 5 years ago.
  • VX1 has a better debt/assets ratio than last year.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • VX1 has an Altman-Z score of 11.80. This indicates that VX1 is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of VX1 (11.80) is better than 85.71% of its industry peers.
  • The Debt to FCF ratio of VX1 is 0.03, which is an excellent value as it means it would take VX1, only 0.03 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of VX1 (0.03) is better than 98.81% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that VX1 is not too dependend on debt financing.
  • VX1's Debt to Equity ratio of 0.01 is amongst the best of the industry. VX1 outperforms 84.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Altman-Z 11.8
ROIC/WACC1.65
WACC9.15%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • VX1 has a Current Ratio of 2.90. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of VX1 (2.90) is comparable to the rest of the industry.
  • A Quick Ratio of 2.46 indicates that VX1 has no problem at all paying its short term obligations.
  • VX1 has a Quick ratio (2.46) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.9
Quick Ratio 2.46
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. VX1.DE Growth Analysis

3.1 Past

  • VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 6248.28%, which is quite impressive.
  • Measured over the past years, VX1 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.27% on average per year.
  • The Revenue has grown by 8.90% in the past year. This is quite good.
  • Measured over the past years, VX1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.10% on average per year.
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.36% on average over the next years. This is quite good.
  • Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 10.31% on average per year.
EPS Next Y5.79%
EPS Next 2Y10.09%
EPS Next 3Y12.27%
EPS Next 5Y12.36%
Revenue Next Year8.81%
Revenue Next 2Y9.61%
Revenue Next 3Y10.47%
Revenue Next 5Y10.31%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

4

4. VX1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 23.74, the valuation of VX1 can be described as rather expensive.
  • VX1's Price/Earnings ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 76.19% of the companies in the same industry.
  • VX1 is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.33, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 22.44, VX1 is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, VX1 is valued a bit cheaper than 78.57% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of VX1 to the average of the S&P500 Index (38.16), we can say VX1 is valued slightly cheaper.
Industry RankSector Rank
PE 23.74
Fwd PE 22.44
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • VX1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 73.81% of the companies in the same industry.
  • 78.57% of the companies in the same industry are more expensive than VX1, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 34.81
EV/EBITDA 20.97
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • VX1 has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as VX1's earnings are expected to grow with 12.27% in the coming years.
PEG (NY)4.1
PEG (5Y)1.93
EPS Next 2Y10.09%
EPS Next 3Y12.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VX1.DE Dividend Analysis

5.1 Amount

  • VX1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VX1.DE Fundamentals: All Metrics, Ratios and Statistics

VERTEX PHARMACEUTICALS INC

FRA:VX1 (4/15/2026, 5:28:00 PM)

370.65

-3.4 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners97.83%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap94.28B
Revenue(TTM)12.00B
Net Income(TTM)3.95B
Analysts82
Price Target477.83 (28.92%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.17%
Min EPS beat(2)-2.79%
Max EPS beat(2)3.12%
EPS beat(4)2
Avg EPS beat(4)-0.85%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)4
Avg EPS beat(8)-64.44%
EPS beat(12)6
Avg EPS beat(12)-43.04%
EPS beat(16)9
Avg EPS beat(16)-31.46%
Revenue beat(2)0
Avg Revenue beat(2)-1.36%
Min Revenue beat(2)-1.51%
Max Revenue beat(2)-1.21%
Revenue beat(4)1
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)0.06%
Revenue beat(8)3
Avg Revenue beat(8)-0.66%
Revenue beat(12)4
Avg Revenue beat(12)-0.75%
Revenue beat(16)6
Avg Revenue beat(16)-0.51%
PT rev (1m)3.6%
PT rev (3m)12.35%
EPS NQ rev (1m)0.76%
EPS NQ rev (3m)-8.74%
EPS NY rev (1m)0.47%
EPS NY rev (3m)-4.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.73%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-0.02%
Valuation
Industry RankSector Rank
PE 23.74
Fwd PE 22.44
P/S 9.26
P/FCF 34.81
P/OCF 30.62
P/B 5.96
P/tB 6.48
EV/EBITDA 20.97
EPS(TTM)15.61
EY4.21%
EPS(NY)16.52
Fwd EY4.46%
FCF(TTM)10.65
FCFY2.87%
OCF(TTM)12.11
OCFY3.27%
SpS40.01
BVpS62.23
TBVpS57.19
PEG (NY)4.1
PEG (5Y)1.93
Graham Number147.836 (-60.11%)
Profitability
Industry RankSector Rank
ROA 15.42%
ROE 21.18%
ROCE 21.51%
ROIC 15.14%
ROICexc 24.16%
ROICexgc 27.17%
OM 39.04%
PM (TTM) 32.94%
GM 86.24%
FCFM 26.61%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
ROICexc(3y)28.92%
ROICexc(5y)41.25%
ROICexgc(3y)35.7%
ROICexgc(5y)59.25%
ROCE(3y)22.47%
ROCE(5y)24.17%
ROICexgc growth 3Y-36.41%
ROICexgc growth 5Y-24.43%
ROICexc growth 3Y-28.98%
ROICexc growth 5Y-17.32%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Debt/EBITDA 0.02
Cap/Depr 208.58%
Cap/Sales 3.65%
Interest Coverage 377.85
Cash Conversion 74.18%
Profit Quality 80.79%
Current Ratio 2.9
Quick Ratio 2.46
Altman-Z 11.8
F-Score7
WACC9.15%
ROIC/WACC1.65
Cap/Depr(3y)195.12%
Cap/Depr(5y)182.1%
Cap/Sales(3y)3.56%
Cap/Sales(5y)3.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
EPS Next Y5.79%
EPS Next 2Y10.09%
EPS Next 3Y12.27%
EPS Next 5Y12.36%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%
Revenue Next Year8.81%
Revenue Next 2Y9.61%
Revenue Next 3Y10.47%
Revenue Next 5Y10.31%
EBIT growth 1Y6.59%
EBIT growth 3Y1.84%
EBIT growth 5Y10.4%
EBIT Next Year7.63%
EBIT Next 3Y14.56%
EBIT Next 5Y11.43%
FCF growth 1Y426.56%
FCF growth 3Y-6.64%
FCF growth 5Y1.3%
OCF growth 1Y837.19%
OCF growth 3Y-4.2%
OCF growth 5Y2.22%

VERTEX PHARMACEUTICALS INC / VX1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.


What is the valuation status for VX1 stock?

ChartMill assigns a valuation rating of 4 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.


How profitable is VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.


What are the PE and PB ratios of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

The Price/Earnings (PE) ratio for VERTEX PHARMACEUTICALS INC (VX1.DE) is 23.74 and the Price/Book (PB) ratio is 5.96.


Can you provide the expected EPS growth for VX1 stock?

The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 5.79% in the next year.